Analysis

Phathom Pharmaceuticals, Inc. (PHAT) Stock Analysis

Phathom Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to PHAT.

websitePHAT/analysis/PHAT

Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to PHAT.

Stock profile

Ticker

PHAT

Asset type

Stock

Market cap

$827.1M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Phathom Pharmaceuticals, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • PHAT primary listing

Latest Phathom Pharmaceuticals, Inc. news

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosi...

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clini...

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel tr...

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

~1.35 million total VOQUEZNA® prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operat...

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT...

Research sections

Valuation

Review valuation context for Phathom Pharmaceuticals, Inc..

Future growth

Review future growth context for Phathom Pharmaceuticals, Inc..

Past performance

Review past performance context for Phathom Pharmaceuticals, Inc..

Financial health

Review financial health context for Phathom Pharmaceuticals, Inc..

Dividend

Review dividend context for Phathom Pharmaceuticals, Inc..

Management

Review management context for Phathom Pharmaceuticals, Inc..

Ownership

Review ownership context for Phathom Pharmaceuticals, Inc..

Other information

Review other information context for Phathom Pharmaceuticals, Inc..

Community

Review community context for Phathom Pharmaceuticals, Inc..